Neuroendocrine effect of a short-term treatment with DHEA in postmenopausal women

Maturitas. 1998 Jan 12;28(3):251-7. doi: 10.1016/s0378-5122(97)00086-8.

Abstract

Objectives: A progressive decline of plasma dehydroepiandrosterone (DHEA) levels occurs in women during aging related to the reduction of adrenocortical secretion. A specific action of DHEA on the central nervous system (CNS) is suggested by the improvement of psychological and physical well-being in postmenopausal women after DHEA supplementation. The aim of the present study was to investigate the neuroendocrine effects of short-term DHEA supplementation in postmenopausal women, evaluating changes of plasma beta-endorphin (beta-EP) and growth hormone (GH) before and after oral DHEA (100 mg/day) for 7 days in postmenopausal women (n = 6).

Methods: Before and after 7 days of DHEA supplementation, postmenopausal women underwent a neuroendocrine test with clonidine, an alpha 2 presinaptic agonist for adrenergic system (1.25 mg i.v.). Basal plasma DHEA, androstenedione (A), testosterone (T), estrone (E1) and estradiol (E2) levels were evaluated before and after treatment, while plasma beta-EP and GH levels were measured before and 15, 30, 45, 60 and 90 min after clonidine injection.

Results: Basal plasma beta-EP and GH levels did not show a significant difference before and after short-term DHEA administration, while circulating A, T, E1 and E2 significantly increased after treatment. The clonidine test induced a significant increase of plasma beta-EP levels in women after receiving DHEA supplementation but not before; conversely, plasma GM levels increased both before and after treatment.

Conclusions: The present study indicates that short-term DHEA supplementation in postmenopausal women is able to restore the impaired response of pituitary beta-EP to clonidine, an alpha 2 presinaptic agonist. According to these data it is possible to hypothesize that DHEA could play a role in the psychological and physical well-being of postmenopausal women acting via a restoration of neuroendocrine control of antero-pituitary beta-EP secretion.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Administration, Oral
  • Androstenedione / blood
  • Androstenedione / metabolism
  • Clonidine
  • Dehydroepiandrosterone / administration & dosage
  • Dehydroepiandrosterone / blood
  • Dehydroepiandrosterone / metabolism
  • Dehydroepiandrosterone / pharmacology*
  • Estrone / blood
  • Estrone / metabolism
  • Female
  • Human Growth Hormone / blood
  • Human Growth Hormone / drug effects*
  • Human Growth Hormone / metabolism
  • Humans
  • Middle Aged
  • Neurosecretory Systems / drug effects*
  • Neurosecretory Systems / metabolism
  • Postmenopause / blood
  • Postmenopause / drug effects*
  • Sympatholytics
  • Testosterone / blood
  • Testosterone / metabolism
  • beta-Endorphin / blood
  • beta-Endorphin / drug effects*
  • beta-Endorphin / metabolism

Substances

  • Sympatholytics
  • Human Growth Hormone
  • Estrone
  • Testosterone
  • Androstenedione
  • Dehydroepiandrosterone
  • beta-Endorphin
  • Clonidine